onlyuse ersonal1

CYCLOPHARM

Investor Presentation

24 May 2022

onlySAFE

useHARBOUR STATEMENT

ersonal2

Certain views expressed here contain information derived from publicly available sources that have not been independently verified.

The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm Limited and as to the markets for the company's products. Such statements, estimates and projections reflect various assumptions made by the directors concerning anticipated results, which assumptions may or may not prove to be correct. Cyclopharm Limited has not sought independent verification of information in this presentation.

While the directors believe they have reasonable grounds for each of the statements, estimates and projections and all care has been taken in the preparation, no representation or warranty, express or implied, is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of statements, estimates and projections contained in this presentation. Such statements, estimates and projections are by their nature subject to significant uncertainties, contingencies and assumptions.

To the maximum extent permitted by law, none of the Cyclopharm Limited, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of information contained in this presentation.

All references to dollars unless otherwise specified are to Australian dollars.

This presentation was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

A World Leading Diagnostic Imaging Company

1

Continued profitability and positive cash flow in

the core business from sales of Technegas

only

across 60 countries with additional revenues

growing from third party distribution

2

Over 4.4 million patient procedures to dated

supported by several guidelines with 100's of

peer reviewed papers highlighting the clinical

use

use of Technegas

3

Progress towards USA market entry -Type B

Meeting held Jan 2022. Targeting mid-2023

for USFDA approval - timeline affirmed

ersonal

Significantly expanding market opportunities

4

"Beyond PE". Key clinical studies soon to be

published expanding clinical applications to

include asthma, COPD, Long COVID…..

35

Strong Balance Sheet to fully fund growth

strategy - $29.25m net cash as at 31 December

2021 with an additional R&D incentive grant

of $2.3m received in January 2022

CYC's

STRATEGIC

PRIORITIES onlyuse ersonal4

1

2

3

4

CYC has clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and lung health space to expand the use of our proprietary products and introduce new innovative technology. We will do this by:

Attaining approval to distribute Technegas in the USA

Expanding the use of Technegas beyond the traditional diagnosis of Pulmonary Embolism into significantly larger applications such as COPD1 and Asthma, Lung Cancer, Pulmonary Hypertension and Long COVID for both diagnosis and patient management.

Identifying, developing and commercialising complementary innovative technologies

Leveraging our core global regulatory strengths (MDR & MDSAP renewal), fiscal discipline, strong balance sheet and well-developed expertise in nuclear medicine and pulmonary healthcare to seek out complementary technologies and businesses

Investor Update

BUILDING FOR GROWTH

Technegas® is a global market leader with significant growth potential in the USA market

onlyuse ersonal5

  • Total global sales of over $93.1m AUD from 2015 to 2021 ($17.7 in FY 2021)
  • Technegas® currently available in over 60 countries
  • Over 4,400,000 patient procedures performed since first approved
  • 1,600 Technegas® generators sold globally since first approved
  • Europe represents 66% of global revenue in 2021
  • Canada was the largest single country market by volume followed closely by France
  • CYC's underlying business is profitable, and the company has a history of paying dividends.
  • Stable gross margins of greater than 72% - (76% in 2020)
  • Over 70% of historical revenue is recurring consumable sales - (73% in 2020)
  • ROW Revenues (ex USA) gradually returning to pre-COVID19 levels
  • Significant COVID-19tailwind resulting from safety concerns that exist with competitive nuclear medicine products…
  • Generator placement rollout strategy to be deployed for rapid USA market penetration and USFDA compliance
  • Significant immediate USA demand

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Cyclopharm Limited published this content on 23 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2022 23:47:01 UTC.